Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- The global AI in antibody discovery market was valued at USD 546.17 million in 2025 and is projected to reach USD 3,162.19 million by 2034, expanding at a CAGR of 21.57%. - North America dominated the market with a 43.72% share in 2025, while the Asia Pacific region is expected to grow at the fastest rate with a CAGR of 23.26%. - Monoclonal antibodies accounted for the largest antibody modality share at 54.41%, driven by established clinical pathways and abundant training datasets for AI model development. - Structure prediction technology led the market with a 32.12% share in 2025, while generative AI and protein language models are forecast to grow at a CAGR of 22.33%.
- Stoke Therapeutics surged 11.42% after presenting positive data for zorevunersen in Dravet syndrome at the 2025 AES Annual Meeting with partner Biogen. - Alpha Tau Medical climbed 25.26% following announcement that the first patient was treated in its pilot study for recurrent glioblastoma multiforme using Alpha DaRT technology. - Senti Biosciences gained 3.92% after the FDA granted RMAT designation to SENTI-202, an investigational CAR-NK cell therapy for acute myeloid leukemia and other hematologic malignancies. - Multiple biotech companies showed strong after-hours performance driven by clinical data presentations, regulatory progress, and financing announcements across various therapeutic areas.
- Absci has accelerated its Phase 1/2a trial for ABS-201, a novel anti-prolactin receptor antibody for androgenetic alopecia, moving the start date to December 2025 from early 2026. - The company will host a virtual seminar on December 11, 2025, featuring leading dermatology experts to discuss the clinical trial path and market potential of ABS-201. - ABS-201 targets prolactin receptors to stimulate hair follicle regeneration and demonstrated statistically significant superior hair regrowth compared to minoxidil in preclinical mouse models. - With approximately 80 million Americans affected by androgenetic alopecia and limited FDA-approved treatment options, ABS-201 represents a potentially transformative therapeutic approach.
- Advanced Micro Devices has formed a strategic collaboration with Oracle Cloud Infrastructure and Absci to advance AI-driven drug discovery using its cutting-edge Instinct MI355X GPUs. - The partnership positions AMD to capitalize on the growing intersection of artificial intelligence and pharmaceutical research, potentially enhancing its market position in high-performance computing sectors. - AMD's stock has shown strong performance with a 34-35% increase over the last quarter, supported by strategic partnerships and positive market sentiment around AI adoption in healthcare. - Despite geopolitical challenges and export restrictions, analysts maintain a consensus price target of $185.77, suggesting potential upside from current trading levels around $155-160.
- Absci, a clinical-stage biotech company, announced a collaboration with Oracle Cloud Infrastructure and AMD to enhance its generative AI Drug Creation Platform for biologics design. - The partnership leverages Oracle's AI infrastructure and AMD's next-generation Instinct MI355X GPUs to accelerate molecular dynamics simulations and antibody design workflows. - The collaboration enables Absci to reduce inter-GPU latency to 2.5 microseconds and achieve terabytes-per-second throughput for large-scale model training and data streaming. - Absci's platform combines AI models with synthetic biology to create novel therapeutics through continuous feedback loops between algorithms and wet lab validation.
- Absci has appointed world-renowned dermatologists Dr. Rodney Sinclair and Dr. David Goldberg to its ABS-201 Scientific Advisory Board to guide clinical development of the AI-designed therapeutic for androgenetic alopecia. - ABS-201 targets prolactin receptors to stimulate hair follicle regeneration and demonstrated statistically significant superior hair regrowth compared to minoxidil in preclinical mouse models. - Phase 1/2a clinical trials are planned to begin in early 2026, with initial proof-of-concept data expected in the second half of 2026 for this potential treatment addressing 80 million Americans with hair loss. - The novel therapeutic approach offers hope for patients with limited options, as current FDA-approved treatments minoxidil and finasteride show limited efficacy and notable side effects.
- Absci has initiated a Phase 1 clinical trial of ABS-101, an anti-TL1A antibody designed using generative AI, marking the company's transition to a clinical-stage biotech. - ABS-101 demonstrates high potency against both monomeric and trimeric TL1A, with potential for quarterly subcutaneous dosing, offering advantages over first-generation anti-TL1A therapies. - The randomized, placebo-controlled study will evaluate safety, pharmacokinetics, and pharmacodynamics in approximately 40 healthy volunteers, with interim data expected in the second half of 2025.
- AMD has invested $20 million in Absci and formed a partnership to power AI-driven drug discovery platforms, marking the chipmaker's strategic entry into pharmaceutical research and development. - Absci's Integrated Drug Creation platform, which can screen billions of cells weekly and produce lab-validated candidates in six weeks, will utilize AMD's high-performance computing solutions for complex biological modeling. - The partnership follows AMD's rival NVIDIA's established presence in AI drug discovery, with Absci already maintaining successful collaborations with major pharmaceutical companies including AstraZeneca, MSD, and Almirall.
